THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY23 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS U…
Award details are derived from public USAspending.gov records. Not a bid recommendation.
Award details
- Award ID
- W81K0022P0269
- Contractor
- DIASORIN MOLECULAR, LLC
- Awarding agency
- Department of Defense
- Sub-agency / office
- Department of the Army
- Award amount
- $111,720
- Period of performance
- Oct 1, 2022 – Sep 30, 2025
- NAICS
- 325413 — In-Vitro Diagnostic Substance Manufacturing
- PSC
- PSC 6550
- Place of performance
- JBSA FT SAM HOUSTON, TX, 782344400, USA
- Competition
- NOT COMPETED UNDER SAP · Set-aside: NO SET ASIDE USED. · 1 offers
- Pricing
- FIRM FIXED PRICE
- Financial breakdown
- Current value $111,720 · Obligated $81,630 · Potential value $139,650 · Latest action obligation $-2,160
Public award description
THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY23 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS USED DURING PERFORMANCE OF THE CONTRACT IN FY23 (01 OCTOBER 2022 - 30 SEPTEMBER 2023).
Find out who's winning similar federal contracts
Discover comparable awards, related contractors, and agency purchasing history.